Matches 1 - 50 out of 108 1 2 3 >


Match Document Document Title
DE102019120667A1 Dosing scheme for BCMAxCD3 antibody constructs  
The present invention relates to an antibody construct comprising a first domain that binds to BCMA and a second domain that binds to CD3 for use in treating or ameliorating a BCMA positive...
DE202016008692U1 Prostate antigen standards and their use  
System for quantifying the levels of a set of prostate antigens, the system comprising: - means for performing an immunoassay to detect the presence of each of the prostate antigens in a sample;...
DE102011118022B4 Antibodies against the prostate-specific stem cell antigen and its use  
The invention relates to recombinant antibodies that bind to prostate-specific stem cell antigen (PSCA). The antibody according to the invention contains complementarity-determining regions (CDR)...
DE102014206881A1 Process for the purification of natural cytotoxic IgM antibodies  
The present invention relates to a preparation of cytotoxic IgM antibodies which is essentially free of non-cytotoxic IgM antibodies and of antibodies of other classes, a method for producing such...
DE102013111487A1 The bispecific antibody fragment and pharmaceutical combination preparation with such a  
The invention relates to a bispecific antibody fragment (10) with a first detection point (12) and at least a second detection point (14), which specifically recognize each at least one structure...
DE112011102350T5 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems  
Die Erfindung liefert eine pharmazeutische Zusammensetzung, umfassend a) eine aktivierte-potenzierte Form eines Antikörpers gegen das Prostata-spezifische Antigen und b) eine...
DE102011118022A1 Antibodies to the prostate specific antigen stem cells and the use thereof  
The invention relates to recombinant to prostate-specific stem cell antigen (PSCA) antibody binding. The antibody of the invention comprises complementarity determining regions (CDR) having the...
DE102007041812A1 Single chain Pan-ecto-nox (SCFV) antibody variable region coding sequence and methods  
The present specification describes compositions and methods for the preparation of a recombinant single (ScFv) antibody with variable region, useful for the detection of members of the Ecto-NOX...
DE102005059242A1 Molecular markers for tumor diagnosis and therapy  
The This invention relates to the diagnosis, prognosis, monitoring and therapy of neoplastic diseases such as tumor diseases, in particular Cancers of the endometrium and their metastases.
DE3571648C5 Monoclonal antibodies to human breast cancer, their production and use, hybridomas for their preparation and the preparation of these hybridomas.  
monoclonal Mouse antibody, of the (A) binds a human breast cancer antigen that of a Control antibody is also attached, by one of the ATCC HB8484 and HB8696 available Hybridomas is formed; (B) has...
DE102004024617A1 Differentially expressed in tumors gene products and their use  
According to the invention were Tumor-associated gene products expressed and coding the for nucleic acids identified. The present invention relates to the therapy and Diagnosis of diseases in...
DE102004023187A1 Identifying surface-associated antigens for tumor diagnosis and therapy  
According to the invention were Tumor-associated gene products expressed and coding the for nucleic acids identified. The present invention relates to the therapy and Diagnosis of diseases in...
DE102004014783A1 The freeze-dried pharmaceutical composition as the conjugate of an antibody with a mytansinoid, for the treatment of cancers, is set to a given concentration and pH value before freeze drying  
A freeze-dried pharmaceutical composition containing a conjugate of an antibody and a maytansinoid which is set to a pH value of 5-6 before freeze drying, is new. It contains a buffer of...
DE10360456A1 Tumor antigens and their use  
The present invention relates to tumor antigens squamous, nucleic acids, encoding them, and antibodies, which are directed against this. The invention further relates to A method of generating...
DE10345010A1 Use of the receptor Nifie14, or nucleic acid encoding it, for detecting cancer, or the risk of developing it, also use of Nifie 14 binding agents for diagnosis and treatment of cancer  
Use of a nucleic acid (I) that encodes a Nifie 14 peptide or protein (II) and/or (II) itself for detecting a cancer, or the risk of developing it, by examining a tissue sample for...
DE10341812A1 Differentially expressed in tumors gene products and their use  
According to the invention were Tumor-associated gene products expressed and coding the for nucleic acids identified. The present invention relates to the therapy and Diagnosis of diseases in...
DE10337368A1 Diagnosis of pancreatic cancer by detecting expression of the a disintegrin and metalloprotease domain 9 (ADAM9) protein using specific antibodies, also therapeutic use of these antibodies and of ADAM9-specific nucleic acids  
Method for diagnosing pancreatic tumors by determining expression of the ADAM9 protein (a disintegrin and metalloprotease domain 9). Isolated cells or tissue sections of pancreas are incubated...
DE10328121A1 Passive immunotherapy against malignant melanoma  
use antibodies for the preparation of a vaccine for immunization against HMW-MAA in Melanomas.
DE10315834A1 Human nucleic acid sequences from pancreatic cancer  
The Invention relates to novel human nucleic acid sequences from pancreatic cancer, thereby encoded proteins or peptides and the uses thereof in connection with the diagnosis and / or treatment of...
DE10296942T5 A therapeutic composition, which changes the immunity reaction  
process to extend of survival a cancer patient, comprising: identifying a patient, which comprises CA125 levels of about 35 units / ml or less, and specific a xenogeneic, for CA125 antigen to the...
DE10314412A1 Genetic immunization with multiple expression constructs for the production of monoclonal antibodies  
disclosed is a process for the production of monoclonal antibodies by means of the method of genetic immunization, in which the genetic Immunization with several encoding different polypeptides...
DE10297379T5 Combination therapy for disease treatment  
process for treating cancer, comprising concurrent administration xenotypischen a monoclonal antibody and a chemotherapeutic Drug to a patient who has cancer.
DE10311248A1 Human monoclonal antibody  
Disclosed is a human monoclonal antibody having heavy and light chain molecules, each having a constant and one from antibody to antibody variable region constructed from antibody to antibody. The...
DE10303664A1 Recognition molecules for the treatment and detection of tumors  
The invention relates to recognition molecules, which are directed against tumors, pharmaceutical compositions comprising said recognition molecules, method for production of the recognition...
DE10256900A1 Tumor-specific recognition molecules  
The invention relates to recognition molecules, which are directed against tumors and can be used for diagnosis and therapy of tumor diseases.
DE10254601A1 Differentially expressed in tumors gene products and their use  
According to the invention, tumor-associated gene products expressed and the nucleic acids encoding them identified. The present invention relates to the therapy and diagnosis of diseases in which...
DE10230909A1 Agents for use in the diagnosis or therapy  
The present invention relates to a specific reagent for detection of the CD30 molecule, said reagent is particularly suited for the diagnosis of lymphoma.
DE10230631A1 Uses of binding to Ngal substances for the diagnosis and treatment of cancer  
The invention relates to uses of Ngal for the diagnosis and treatment of cancer and screening for substances for such purposes.
DE10229907A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans  
A purified polypeptide that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, is new. The polypeptide specifically binds to at least...
DE10229906A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans  
A purified polypeptide that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, is new. The polypeptide specifically binds to at least...
DE10230516A1 New purified polypeptide (e.g. an antibody) that induces apoptosis of a neoplastic cell, useful for diagnosing or treating a neoplasm or a proliferative disorder in mammals, including humans  
A purified polypeptide that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, is new. The polypeptide specifically binds to at least...
DE10210427A1 Human monoclonal antibody  
A human monoclonal antibody with heavy and light chain molecules is described, each of which has an antibody-to-antibody constant and an antibody-to-antibody-variable region. According to the...
DE10211088A1 Gene products differentially expressed in tumors and their use  
According to the invention, tumor-associated expressed gene products and the nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases...
DE10210239A1 Specific Ab1 'antibodies to the tumor-associated antigen CA125  
The present invention relates to specific anti-anti-idiotypic antibodies which react with anti-idiotypic anti-CA125 antibodies and are specific for the tumor-associated antigen CA125. In...
DE10210425A1 New glycoprotein receptor on surface of cancer cells, useful for treatment and diagnosis of cancer and for drug screening, also new specific antibody  
Glycoprotein receptor (I), present on the surface membrane of strongly proliferating cells, especially stomach carcinoma, having at least one determinant that corresponds with a determinant of...
DE10156482A1 Bispecific antibody molecule  
A first bispecific antibody molecule comprises at least one binding site with a variable domain on a light chain (VL) and a variable domain for the T-cell receptor CD-28, linked thereto on a heavy...
DE10143775A1 Selection and determination of specific cells, useful particularly for diagnosis and monitoring of tumors, by antibody-mediated selection then detecting specific mRNA  
Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample, is new. Method for selection and/or qualitative and/or quantitative...
DE10143776A1 Selection and determination of specific cells, useful particularly for diagnosis and monitoring of tumors, by antibody-mediated selection then detecting specific mRNA  
Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample, is new. Method for selection and/or qualitative and/or quantitative...
DE10136009A1 New glycoprotein receptor on surface of cancer cells, useful for treatment and diagnosis of cancer and for drug screening, also new specific antibody  
Glycoprotein receptor (I), present on the surface membrane of strongly proliferating cells, especially stomach carcinoma, having at least one determinant that corresponds with a determinant of...
DE10117381A1 Production of polyclonal, monospecific antibodies against uPAR variants del4, del5 and del4 + 5 and their use for diagnostic and therapeutic purposes  
The invention relates to the production of specific antibodies to detect human tumour-associated urokinase-type plasminogene activator receptor (uPAR) deletion variants in biological samples and...
DE10063048A1 Single-chain antibody with improved stability  
Disclosed is a single-chain antibody which is characterized in that the C-terminus of V¶H¶ domain is linked directly without a linker to the N-terminal of V¶L¶ domain, the domain V¶H¶ a deletion...
DE10055285A1 New marker for the diagnosis and therapy of tumors  
The present invention relates to novel markers for tumors, preferably CTCL. The present invention further relates to their use for the diagnosis or treatment of tumor diseases, preferably CTCL.
DE10043437A1 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites  
The invention relates to the use of a pharmaceutical preparation, containing a trifunctional bispecific and/or trispecific antibody with the following properties: a) binding to a T-cell; b)...
DE10025521A1 Tumor-associated antigen B132  
The invention relates to the tumor-associated antigen B132, to the immunogenic peptides derived therefrom and to the DNA molecules encoding the same. The invention further relates to the use...
DE19947559A1 Antibody-dye conjugates against targets of angiogenesis for intraoperative tumor edge representation  
Are antibody-dye conjugates that are suitable for binding to structures of newly formed vessels and described their use for intraoperative visualization of pathological angiogenesis.
DE10027695A1 Vaccines against conformation-dependent or non-peptide antigens, based on DNA encoding peptide which mimics the antigen, useful e.g. as antitumor vaccines  
A vaccine (V1) against conformation-dependent antigens (CDA) comprising DNA (I) and/or an antibody, or peptide which immunologically imitates CDA, is new. A vaccine (V1) against...
DE19943839A1 Contactinhibin medicated and medicine that contains antibodies directed against contactinhibin  
A medicament containing contactinhibin, variants or components thereof inducing anti-contactinhibin antibodies after administration. Also disclosed is a medicament containing anti-contactinhibin...
DE19936563A1 Tumor associated antigen  
The invention relates to tumor-associated antigens, immunogenic peptides derived therefrom and the DNA molecules coding therefor as well as to their utilization in cancer immunotherapy.
DE19924199A1 Tumor associated antigen  
The invention relates to a tumor-associated antigen, to immunogenic peptides derived therefrom, to coding DNA molecules that code therefor, and to their use in the immune based therapy of cancer...
DE19903495A1 Ewing tumor antigen and nucleic acid  
The invention relates to a nucleic acid coding for a polypeptide which is expressed by Ewing's tumours and is detected by antibodies or cytolytic cells as a characteristic antigen of the tumour.

Matches 1 - 50 out of 108 1 2 3 >